Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Unknown 2Terminated 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Prostatic Neoplasms 138Breast Neoplasms 95Neoplasms 8Neoplasm Metastasis 6Breast Neoplasms, Male 6Advanced Breast Cancer 4Salivary Gland Neoplasms 3Prostate Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Osteoporosis 2Leiomyoma 2Infertility 2Advanced Prostate Cancer 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Sarcopenia 1Radiation Injuries 1Primary Ovarian Insufficiency 1Primary Dysautonomias 1Patients With T1-4 Advanced Prostate Cancer 1Patient Compliance 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Osteitis Deformans 1Myofibroma 1Lymphatic Metastasis 1Kidney Diseases 1Inflammatory Breast Neoplasms 1

Interventions

Fulvestrant 18Letrozole 10Anastrozole 8Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Goserelin 4Docetaxel 4pyrotinib 3exemestane 3Vinorelbine 3Injections 3Aromatase Inhibitors 3trastuzumab deruxtecan 2toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2dalpiciclib 2abemaciclib 2Trastuzumab 2Gonadotropin-Releasing Hormone 2FCN-437c 2Everolimus 2Dasatinib 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Breast Cancer × Goserelin × Clear all
NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

EQRx International, Inc.

Phase 2 Terminated
100 enrolled 14 charts
Breast

Advanced Breast Cancer

NCT04862143 2024-06-20

TELEPIK

Novartis

Phase 2 Terminated
2 enrolled 10 charts
Breast

Advanced Breast Cancer

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
434 enrolled
Breast

Advanced Breast Cancer

NCT05438810 2022-07-05

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
312 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡